A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Astellas Pharma Inc
Fate Therapeutics
Fate Therapeutics
Jules Bordet Institute